Genetics, LRRK2, Mitochondrion, Cell biology and Parkinson's disease are his primary areas of study. His LRRK2 research is multidisciplinary, incorporating elements of Leucine-rich repeat and Kinase activity. His Mitochondrion research integrates issues from Oxidative stress, PINK1 and Molecular biology.
He has researched Cell biology in several fields, including Parkin, Neurodegeneration and Substantia nigra. His study of Alpha-synuclein is a part of Parkinson's disease. His Disease research includes elements of Neurology, Neuroscience and Toxicity.
His scientific interests lie mostly in Genetics, LRRK2, Cell biology, Disease and Parkinson's disease. His study in Genetics is interdisciplinary in nature, drawing from both Parkin and Parkinsonism. His research integrates issues of Leucine-rich repeat, Kinase, Kinase activity and GTPase in his study of LRRK2.
His biological study deals with issues like PINK1, which deal with fields such as mitochondrial fusion. His Disease research is multidisciplinary, relying on both Neuroscience and Bioinformatics. His work is connected to Alpha-synuclein and Synuclein, as a part of Parkinson's disease.
His primary areas of investigation include LRRK2, Disease, Cell biology, Parkinson's disease and Genetics. His research in LRRK2 intersects with topics in GTPase, Rab and Kinase, Kinase activity. His Disease research includes themes of Genome-wide association study, Computational biology, Gene and Oncology.
His work in the fields of Phosphorylation overlaps with other areas such as Voltage-dependent anion channel. His Parkinson's disease study also includes fields such as
Mark R. Cookson mostly deals with LRRK2, Disease, Cell biology, Genetics and Parkinson's disease. His work deals with themes such as Oxidative phosphorylation, Kinase activity, Neuroinflammation, SOD2 and Neuroscience, which intersect with LRRK2. Mark R. Cookson has included themes like GTPase, Rab and Gene in his Disease study.
His Cell biology study incorporates themes from Vesicle and Lysosome. Mark R. Cookson combines Genetics and DNAJC5 in his research. His Parkinson's disease study combines topics from a wide range of disciplines, such as Phagocytosis, Phagocytic dysfunction, Molecular medicine, Degeneration and Apoptosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif.
Autophagy (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Autophagy (2012)
α-Synuclein Locus Triplication Causes Parkinson's Disease
A. B. Singleton;M. Farrer;J. Johnson;A. Singleton.
Science (2003)
PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.
Derek P. Narendra;Seok Min Jin;Atsushi Tanaka;Der Fen Suen.
PLOS Biology (2010)
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Javier Simón-Sánchez;Claudia Schulte;Jose M Bras;Jose M Bras;Manu Sharma.
Nature Genetics (2009)
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization.
Rosa M. Canet-Avilés;Mark A. Wilson;David W. Miller;Rili Ahmad.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain
J. Raphael Gibbs;J. Raphael Gibbs;Marcel P. van der Brug;Marcel P. van der Brug;Dena G. Hernandez;Dena G. Hernandez;Bryan J. Traynor.
PLOS Genetics (2010)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
Mike A Nalls;Cornelis Blauwendraat;Costanza L Vallerga;Karl Heilbron.
Lancet Neurology (2019)
THE BIOCHEMISTRY OF PARKINSON'S DISEASE*
Mark R. Cookson.
Annual Review of Biochemistry (2005)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
Elisa Greggio;Shushant Jain;Ann Kingsbury;Rina Bandopadhyay.
Neurobiology of Disease (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
University College London
National Institutes of Health
University College London
National Institutes of Health
University College London
National Institutes of Health
National Institutes of Health
National Institutes of Health
KU Leuven
National Technical University of Athens
Virginia Tech
University of Science and Technology of China
Griffith University
University of New South Wales
Erasmus University Rotterdam
University Medical Center Groningen
University of Toronto
École Polytechnique Fédérale de Lausanne
University of Angers
University of Western Australia
City University of New York
University of Bristol
Vanderbilt University Medical Center
Mario Negri Institute for Pharmacological Research
Duke University